Veea jumps on an officer-change filing
VEEA is up 47.3%, the largest move on the list. The only item behind it is an SEC 8-K covering Item 5.02 (departure or election of directors and officers, plus compensatory arrangements) and Item 8.01 other events. That's a headline-level filing notice, so there's nothing here explaining why a governance filing would carry a move that size.
AST SpaceMobile down 10.5% despite good operational news
ASTS fell 10.5%, to $50.97 at the time of the GuruFocus piece, against a 52-week range of $47.57 to $133.86. The stated pressure is competitive: SpaceX's recent spectrum acquisition has unsettled the satellite communications sector. Against that, three positive items landed over the weekend and into Monday, and Investing.com reported the stock up 2.7% pre-open on them. Deutsche Bank upgraded ASTS from Hold to Buy with a $93 target. BlueBird satellites 14, 15 and 16 arrived at Cape Canaveral, and the FCC granted a 30-day special temporary authorization to test 900-MHz radiolocation across the contiguous US and Hawaii, with the Space Development Agency backing the application as part of its look at commercial satellite architectures for military use. TELUS and AST also completed a first terrestrial-to-space integration test in Canada. Separately, AST's CEO pointed out that its US telecom partners hold roughly 1,000 MHz of low and mid-band spectrum that can run through its constellation, which alongside AST's own 45 MHz L-band allocation is meant to deliver peak speeds near 200 Mbps. On the numbers, GuruFocus flags P/S of 121.57 versus a historical median of about 62, no meaningful P/E given TTM EPS of -2.14 and operating margins worse than -400%, debt-to-equity of 1.58, a GF Score of 44/100, and insider selling of $451.6m against $0.8m of buying over twelve months. Its GF Value of $579.19 is labelled a possible value trap by the same outlet.
Sezzle up 9.7% with a Form 144 filed
SEZL rose 9.7% to $128.64, inside a 52-week range of $49.50 to $195.71. Neither item gives a reason for the move. GuruFocus puts GF Value at $95.31, so the price sits 35% above it, with a TTM P/E of 28.0x against a five-year median of 25.7x and a forward P/E of 19.3x. GF Score is 81/100, strongest on growth (9/10), weakest on profitability (4/10). Insiders sold $26.8m and bought $0.1m over the past year, and one guru holds the stock with three trimming. A Form 144 was filed for 10 October, headline only beyond the filing itself.
Datadog at an all-time high, heavy insider selling
DDOG is up 7.1% to $293.26, an all-time high of $292.80 intraday, market cap around $105bn, up 101% year to date and about 84% over twelve months on an 80% gross margin and 32% revenue growth. CTO and director Alexis Le-Quoc sold 53,912 Class A shares for $14,750,067 on 7 October at $270.85 to $280.60 under a 10b5-1 plan set up in June 2025, leaving him 488,033 shares directly plus trust holdings. GuruFocus counts $913.5m of insider selling over twelve months with no buying, $272.6m of it in the last three months. The analyst side is uniformly positive: CIBC's Todd Coupland kept Outperformer and raised his target to $315 from $280, Yorkville Ives initiated at outperform with $335, FBN Securities at outperform with $325, Wedbush at Outperform with $275 citing Q2 FY26 revenue growth accelerating to 36% year on year from 28%, Mizuho reiterated Outperform at $300, and Stifel kept Buy at $305 noting OpenAI spending with Datadog averaging $80-85m per quarter in FY25 and reaching the low $100m range in Q2 2026. GuruFocus reads it the other way, calling the stock 42.6% above its $205.66 GF Value on a 598.5x TTM P/E versus a 418.9x five-year median, with a GF Score of 84/100.
CRISPR up on ARK buying
CRSP rose 5.8%. ARK's Friday trade file shows it added 21,487 shares to ARKG, worth $1.08m. The same file had ARK selling 397,016 DraftKings shares for about $7.89m across ARKW and ARKF, trimming 57,911 CareDx shares for $3.60m, selling 22,276 SpaceX shares for $3.58m, and buying Guardant Health, Nurix, Intellia, Alamar, Beam and Compass Pathways while selling AMD, Alphabet and Shopify. The $1.08m buy is small relative to the move, so this isn't a full explanation.
Vertical Data up 5.6% on Form 4s only
VDTA is up 5.6%. The two items are bare Form 4 filings for 9 and 10 October with no detail published, so there's nothing explaining the move.
Joby down 5.4% at a 52-week low, with a Barclays downgrade
JOBY fell 5.4% to $5.44, close to its 52-week low of $5.23 and down 59% year to date. The full-text item is routine: CEO JoeBen Bevirt sold 15,789 shares at $5.95 on 2 October for $93,944, purely to cover tax on vesting RSUs, leaving 254,519 shares held directly plus very large indirect stakes through The Joby Trust (57.2m shares) and the 2020 Descendants Trust (31.7m). The more relevant headline-only item is a Barclays downgrade to Underweight with the target cut to $4, alongside a GuruFocus headline saying shares sank 8% to a 52-week low and two further small insider sales including $30,645 by the chief policy officer. Background from the same article: Q2 2026 revenue was $38.6m, up from roughly $15,000 a year earlier and $24.2m in Q1, beating a $29-30m consensus, with Blade passenger contributing $36.2m. Joby also agreed to buy defence firm Resonant Sciences for about $500m. H.C. Wainwright has a Buy and $18 target, Cantor Fitzgerald Neutral.
SpaceX spectrum deal ripples through telecom
SPCX itself is up only 1.2%, but the headlines around it tie together several other names today. The repeated line is an $8bn spectrum acquisition that has telecoms repricing: Australian and New Zealand telecom shares tumbled, US tower REITs rallied (Crown Castle up nearly 20% per one headline), and the same competitive worry is named explicitly as the drag on ASTS. Other SpaceX headlines cover Venezuela authorising Starlink nationwide, Musk promising to compete on price in India ahead of Reliance Jio's IPO, Barclays initiating coverage at Overweight, and United adding TBS to Starlink flights. Barclays also initiated Rocket Lab at Overweight, with RKLB roughly flat at -0.3%.
Smaller movers, headline only
Starfighters Space is down 4.8% with an 8-K on bylaw amendments and fiscal year change. Teva is up 4.7% with a conference call transcript and a GF Value note. Oracle is up 4.6% with a cluster of chart posts and GuruFocus headlines on an AI-story lift and a $3.5m insider purchase, and a GF Value note putting fair value at $194.91 against a $141.40 price. Xometry +4.3%, Dave +4.3%, AngloGold +3.7%, Coherent +3.4%, Itau +3.4% (Goldman raised its target to $10.50), On Holding +3.1%, NetApp +2.9%, Butterfly Network +2.7% on small CAO sales.
Insider selling clusters at Arista and Astera Labs
ANET is up 2.7% and dominates the list by item count, but it's the same event told nine ways: CEO Jayshree Ullal sold $21.06m of stock, reported across multiple Form 4 and Form 144 filings for 9 through 11 October. A separate headline notes Arista rising as Ethernet moves into Nvidia's territory. ALAB is down 1.4% with a similar pattern, director Stefan Dyckerhoff selling $4.7m across repeated filings, plus a Northland downgrade tied to AI semiconductor earnings concerns and ETFs net sellers on 8 October.
Megacaps quiet
Apple is down 1.1%, with most of its items being routine ETF flow reports. The substantive headlines are iPhone 18 Pro order cuts and which suppliers are exposed, plus Luxshare downplaying a US patent probe. TSMC is down 1.0% ahead of earnings, with a headline noting shares fell despite a 55% September sales surge. Micron -0.7% with an expanded buyback headline, Broadcom +0.4% with its CEO saying capital, not memory chips, is the main constraint on AI growth. Adobe, Accenture, Costco, Generac, Aflac and the rest are flat and carry nothing beyond filings.
Veea jumps on an officer-change 8-K
The biggest move in the list is Veea, up 47.3%, and all that sits behind it here is an SEC 8-K headline covering Item 5.02 (departure or election of directors and officers, plus compensatory arrangements) and Item 8.01 other events. No article text, so the filing itself is the only thing to look at if you want the reason.
AST SpaceMobile at a 52-week low on SpaceX competition
ASTS fell 10.5% to around $48-51, a fresh 52-week low that broke the prior $49.31 floor, against a 52-week high of $133.86 and a one-year change of about -39%. The stated driver is competition: the FCC authorised SpaceX to build a 15,000-satellite direct-to-cell network, which hits ASTS's carrier-dependent model, and the FCC's Oct 29 agenda includes a proposed 25 MHz auction in bands usable for direct-to-device. Also cited as weighing on it: six straight earnings misses, a $125.9M BlueBird 7 write-off, a $1B convertible offering, and William Blair cutting its 2027 revenue estimate to $459M from $752M while holding Market Perform. B.Riley downgraded to Neutral with a $65 target, Roth MKM kept Buy at $108, Berenberg's Michael Filatov reaffirmed Buy (initiated at $92) arguing the pending FCC approval of Grain Management's nationwide spectrum sale to SpaceX actually raises ASTS's relevance as a carrier-aligned satellite partner, and Cantor Fitzgerald has Overweight at $90. Options volume was 253,920 contracts, calls 158,506 versus puts 95,414, with heavy fresh call buying in the Oct 16 $50/$55/$60 and Nov 20 $55 strikes (volume several times open interest), while the single largest contract was the Jan 15 2027 $50 put at 10,372 against 5,844 open interest. Three-month vol rose 4.55 points to 81.31%. On fundamentals, GuruFocus has ASTS at a P/S of roughly 119-122x versus a 62x historical median, no meaningful P/E on a -2.14 TTM EPS, GF Score 44/100, debt-to-equity 1.58, and insiders net sellers of $450.8M over twelve months ($451.6M sold, $0.8M bought). Separately, management pointed to US partners holding about 1,000 MHz of low and mid-band spectrum usable through its constellation plus its own 45 MHz L-band, targeting peak speeds near 200 Mbps, and ASTS and TELUS completed a first integration test with service expected within a year.
The SpaceX spectrum deal running through the whole list
The ASTS story is the same thread driving a large headline cluster: SpaceX's roughly $8 billion spectrum acquisition from Grain Management (one headline prices it at $571M per MHz) sent telecom names down hard, with T-Mobile, AT&T and Verizon all showing double-digit declines in the market-mover tables, while tower REITs Crown Castle, American Tower and SBA Communications rallied. Headlines also cover Barclays initiating SPCX at Overweight, TD Cowen reiterating Buy with a $200 target, Starlink being authorised to operate in Venezuela, and a public spat between Musk and Reliance over Starlink pricing in India ahead of the Jio IPO. SPCX itself was up only 1.2%. Rocket Lab, also down 0.3%, got a Barclays initiation at Overweight and a TD Cowen target cut to $90, headline-only.
Datadog at an all-time high
DDOG rose 7.1% to $293.26, an all-time high, roughly a 101% year-to-date and 84% one-year gain, market cap about $105 billion, on 80% gross margin and 32% revenue growth. Second-quarter fiscal 2026 revenue growth accelerated to 36% year-over-year from 28%, and Stifel estimates OpenAI's spend with Datadog reached the low $100 million range in that quarter after averaging $80-85 million per quarter in FY25. CIBC's Todd Coupland kept Outperformer and raised his target to $315 from $280; Yorkville Ives initiated at Outperform/$335, FBN Securities Outperform/$325, Wedbush Outperform/$275, Mizuho Outperform/$300, Stifel Buy/$305. Against that, CTO and director Alexis Le-Quoc sold 53,912 Class A shares for $14,750,067 on 7 October at $270.85 to $280.60 under a 10b5-1 plan set up in June 2025, leaving him with 488,033 shares directly; insiders have sold $913.5M over twelve months with no buying. GuruFocus scores DDOG 84/100 and calls it 42.6% overvalued against a GF Value of $205.66, with a TTM P/E of 598.5x versus a 418.9x five-year median. A Form 144 and further Form 4 filings also hit.
Sezzle and other mid-size gainers
Sezzle was up 9.7% to $128.64, within a 52-week range of $49.50 to $195.71, with a Form 144 filed 10 October. GuruFocus puts it 35% above its $95.31 GF Value, GF Score 81/100 (growth 9/10, profitability 4/10), P/E 28.0x versus a 25.7x five-year median, and insiders net sellers of $26.7M over the past year. CRISPR Therapeutics rose 5.8%; ARK added 21,487 CRSP shares ($1.08M) to ARKG on 9 October, alongside buys in Guardant Health, Nurix and Intellia, and sales of DraftKings ($7.89M), CareDx ($3.60M) and SpaceX ($3.58M). Vertical Data was up 5.6% with only Form 4 filings behind it.
Joby, Oracle, Teva, Nio
Joby fell 5.4% on headline-only items: Barclays downgraded it to Underweight and cut its target to $4, one headline says shares sank 8% to a 52-week low, and the chief policy officer sold $30,645 of stock. Oracle rose 4.6% with a thick headline cluster but no full text, covering an AI-related lift, scrutiny of OpenAI metrics alongside Microsoft, an insider putting $3.5 million into the stock, and a GuruFocus note citing a $194.91 GF Value against a $141.40 price. Teva gained 4.7%, with headlines pointing to FDA approval of Weltruza, its injectable antipsychotic. Nio rose 5.0% on a headline asking why it was surging; the reason isn't given here. Starfighters Space fell 4.8% on an 8-K covering a bylaw or fiscal-year amendment.
Insider filings and small analyst moves
A long tail of Form 4 and 144 filings sits under names that barely moved: Arista's CEO Jayshree Ullal sold about $21 million (ANET +2.7%), Astera Labs director Stefan Dyckerhoff sold $4.7 million (ALAB -1.4%, also a Northland downgrade), plus smaller sales at Butterfly Network, Si-Bone and Generac. Target changes by headline only: Goldman raised ITUB to $10.50, RBC raised EXEL to $51, Barclays cut PYPL to $56, Citi cut KGS to $82, KBW cut AFL to $120, JPMorgan cut FPS to $49, UBS raised Marathon Petroleum on refining margins, and GLJ kept VRT at Sell.
Quieter names
Netflix slipped 1.8% with headlines on a reported 5% workforce cut and Skydance debt; Apple fell 1.1% on iPhone 18 Pro order-cut reports, with Evercore ISI reiterating its rating on lead times; TSMC eased 1.0% despite headlines citing a 55% September sales surge and a Q3 revenue beat. The rest of the list, including Micron, Broadcom, Costco and Coherent, is routine filings and commentary with sub-1% moves.
Veea jumps 47% on an officer-change 8-K
Veea is up 47.3%, the largest move on the list, against an SEC 8-K filing covering Item 5.02 (departure of directors or officers, election of directors, appointment of officers and compensatory arrangements) and Item 8.01 (other events). That's the headline of the filing index entry only, so I can't tell you who left, who arrived, or whether the move is connected to it. Worth opening the filing itself if you hold this.
Opennode down 17% with no explanation in the material
OPNW is down 17.0%. The only item attached is an Investing.com page for a Form 4 filed on 9 October, and the page carries no substance at all beyond the headline, no insider name, no share count, no price. Nothing here explains the drop.
AST SpaceMobile breaks to a 52-week low
ASTS is down 10.5% and made a fresh 52-week low, trading near $48-49 against a 52-week high of $133.86, roughly 61% off the high and down about 39% over a year. The trigger is competitive and regulatory: the FCC authorised SpaceX to build a 15,000-satellite direct-to-cell network on its own spectrum, which bypasses wireless carriers and so hits AST hardest, since AST's whole go-to-market runs through carriers. On top of that, the FCC's October 29 agenda came out a day early and contains two items, one opening more airwaves to leasing under Supplemental Coverage from Space rules and one proposing to auction 25 MHz in bands usable for direct-to-device. Clear Street called it a mixed signal and kept its Buy. The stock was already weak going in: a B. Riley downgrade to Neutral on October 2 with the target cut from $85 to $65, William Blair cutting its 2027 revenue estimate from $752m to $459m on launch delays, six straight earnings misses, a $125.9m write-off on the failed BlueBird 7 satellite, and a $1bn convertible offering that pushed the 45-satellite constellation target into early 2027. Technically it sits below its 20-day and 200-day averages with a death cross from July. Roth MKM is the loud bull, reiterating Buy at $108, and Berenberg's Michael Filatov reaffirmed Buy, arguing the pending FCC approval of Grain Management's spectrum sale to SpaceX actually raises AST's relevance as a carrier-aligned partner. Options flow was heavy at 253,920 contracts, call-skewed by count (158,506 calls to 95,414 puts), with fresh buying in Oct 16 $50/$55/$60 and Nov 20 $55 calls at multiples of open interest, while the single largest line was the Jan 2027 $50 put at 10,372 contracts. Three-month implied vol rose 4.55 points to 81.31%. The GuruFocus pieces add context rather than news: P/S of about 120x against a 62x historical median, GF Score 44/100 with profitability 1/10, and insiders net sellers of $450.8m over twelve months against $0.8m of buying. Their GF Value of $579 is flagged by their own write-up as a possible value trap given the losses.
Sezzle up 9.7% alongside a Form 144
SEZL rose 9.7% to $128.64 on volume of 669,317 shares, which Yahoo's chart note puts at roughly 0.4x the 20-day average, so the move came on light turnover. A Form 144 was filed for 10 October, with no detail given in the article. GuruFocus flags the stock as 35% above its $95.31 GF Value, a P/E of 28.0x versus a 25.7x five-year median, a GF Score of 81/100 (growth 9/10, profitability 4/10), and net insider selling of $26.7m over the past year against $0.1m of buying. The 52-week range is $49.50 to $195.71. TD Cowen maintained Buy on 6 October while trimming its target from $165 to $160. Earnings are dated 4 November.
Datadog at an all-time high, with the CTO selling
DDOG rose 7.1% to $293.26, an all-time high of $292.80 intraday, market cap about $105bn, up 101% year to date and about 84% over twelve months. CIBC's Todd Coupland maintained Outperformer and lifted his target from $280 to $315. The bull case in the coverage rests on revenue growth accelerating to 36% year-over-year in fiscal Q2 2026 from 28% the prior quarter, an 80% gross margin, and OpenAI spend running at roughly $80-85m a quarter in FY2025 by Stifel's estimate, reaching the low $100m range in Q2 2026. Recent initiations: Yorkville Ives Outperform at $335, FBN Securities Outperform at $325, Wedbush Outperform at $275, Mizuho Outperform at $300, Stifel Buy at $305. Against that, CTO and director Alexis Le-Quoc sold 53,912 Class A shares for $14,750,067 on 7 October at $270.85 to $280.60 under a 10b5-1 plan dated June 2025, leaving him with 488,033 shares directly; a Form 144 was also filed for 10 October. GuruFocus puts the stock 42.6% above its $205.66 GF Value with a trailing P/E of 598.5x versus a 418.9x five-year median, and counts $913.5m of insider selling over twelve months with no buying.
The SpaceX spectrum deal running through the whole list
The single largest connective thread today is SpaceX's roughly $8bn acquisition of a nationwide low-band spectrum portfolio, which the headlines price at $571m per MHz. SPCX itself is up only 1.2%, but the knock-on is everywhere: the telecom incumbents fell hard (T-Mobile, AT&T and Verizon all appear among the day's biggest losers in the quote tables embedded in these articles), tower REITs rallied, with Crown Castle up 19.87% per one headline, and ASTS broke down as described above. Barclays initiated SPCX at Overweight and TD Cowen reiterated Buy with a $200 target citing the spectrum purchase. Separate SpaceX headlines cover Venezuela authorising Starlink nationwide, Musk sparring publicly with Ambani over Starlink pricing in India ahead of the Jio IPO, and United adding TBS to Starlink flights. These are headlines only, so the detail behind each is limited to what's stated.
Mid-sized movers with headline-only coverage
Joby is down 5.4% at a 52-week low of $5.57, with Barclays downgrading to Underweight and cutting its target to $4. Teva is up 4.7% on FDA approval of Weltruza, an injectable antipsychotic. Oracle is up 4.6%, with a cluster of headlines around AI sentiment, an insider purchase described as $3.5m, and scrutiny of OpenAI's numbers; no single item explains the move and I only have the headlines. CRISPR Therapeutics is up 5.8% with ARK reported as a buyer while selling DraftKings. NIO is up 5.0% on a "why is it surging" piece I haven't read. Vertical Data up 5.6% on two Form 4s, Starfighters Space down 4.8% on a bylaws-amendment 8-K. Coherent is up 3.4%, tied to Lumentum's CEO saying AI optical components are sold out through 2029.
Quiet names and routine filings
The rest of the section is mostly insider Form 4s and small analyst adjustments with little price reaction: Arista CEO Jayshree Ullal sold $21.06m (stock +2.7%), Astera Labs director Stefan Dyckerhoff sold $4.7m (stock -1.4%, with a Northland downgrade also flagged), plus small sales at Butterfly Network and Si-Bone. Apple is down 1.1% against a large but low-signal pile of headlines, the recurring one being a report of iPhone 18 Pro order cuts. TSMC is down 1.0% despite headlines citing a 55% September sales rise and a Q3 revenue beat. Netflix is down 1.8% with headlines on a reported 5% workforce cut and Skydance debt. Micron, Broadcom, Costco, Rocket Lab and the remaining analyst-note items moved less than 1% and have nothing behind them worth your time today.
Biggest movers with the least behind them
The two largest moves on the list are also the thinnest on explanation. Veea is up 47.3% alongside an 8-K covering a departure or appointment of directors and officers, compensatory arrangements, and an Item 8.01 other-events disclosure; that's the headline, and nothing in the list says what the filing actually contains. OpenWorks is down 17.0%, and the only item attached is a Form 4 insider filing notice for VerifyMe dated 9 October, which carries no detail at all beyond the fact of the filing. Both need the primary documents if you care.
AST SpaceMobile breaks to a 52-week low
ASTS is down 10.5%, trading around $49.25 against a 52-week low of $49.31 and a high of $133.86, roughly 61% off that high and down 38.8% over the year. The trigger was the FCC authorising SpaceX to build a 15,000-satellite direct-to-cell network on its own spectrum, which bypasses wireless carriers entirely and so cuts at AST's carrier-partnership model harder than at the rest of the space group. Added to that, the FCC's 29 October agenda came out a day early and includes a proposal to auction 25 MHz in bands usable for direct-to-device service plus wider leasing under Supplemental Coverage from Space rules; Clear Street called it a mixed signal and kept its Buy. The stock was already carrying a B. Riley downgrade to Neutral on 2 October with the target cut from $85 to $65, a William Blair cut to 2027 revenue from $752m to $459m on launch delays, six consecutive earnings misses, a $125.9m write-off on the BlueBird 7 failure, and a $1bn convertible that pushed the 45-satellite constellation target into early 2027. Roth MKM is the counterweight, reiterating Buy at $108, and Berenberg's Michael Filatov reaffirmed Buy on the view that SpaceX buying Grain Management's nationwide spectrum raises AST's value as the carrier-aligned alternative. AT&T and Verizon spectrum arrangements are described as intact, and management points to partners holding roughly 1,000 MHz of low and mid-band spectrum plus AST's own 45 MHz L-band allocation, targeting peak speeds near 200 Mbps. Options flow was heavy at 253,920 contracts, skewed to calls 158,506 versus 95,414 puts, though the single biggest line was the January 2027 $50 put at 10,372 contracts against 5,844 open interest; three-month implied volatility rose 4.55 points to 81.31%. GuruFocus flags insider selling of $451.6m against $0.8m of buying over twelve months, a GF Score of 44/100, and a price-to-sales of about 120x versus a 62x historical median, while its own GF Value model prints $579 a share and labels it a possible value trap.
Sezzle up on a Form 144 day
Sezzle is up 9.7% to $128.64, inside a 52-week range of $49.50 to $195.71. A Form 144 notice of proposed insider sale was filed on 10 October, with no detail published beyond the filing itself. GuruFocus puts GF Value at $95.31, making the current price a 35% premium, with a GF Score of 81/100 driven by growth at 9/10 against profitability at 4/10, a trailing P/E of 28.0x versus a 25.7x five-year median, and net insider selling of $26.7m over the past year. TD Cowen kept a Buy on 6 October while trimming its target from $165 to $160. Earnings are set for 4 November. Nothing in the material explains the day's gain.
Datadog at an all-time high on a CIBC raise
Datadog rose 7.1% to $293.26, an all-time high, taking market cap to roughly $105bn and the year-to-date return above 100%. CIBC's Todd Coupland kept an Outperformer rating and raised the target from $280 to $315. Separately, CTO and director Alexis Le-Quoc sold 53,912 Class A shares for $14.75m on 7 October at $270.85 to $280.60 under a 10b5-1 plan set up in June 2025, leaving him 488,033 shares held directly; GuruFocus counts $913.5m of insider selling over twelve months with no purchases. The bull case cited across the coverage is revenue growth accelerating to 36% year-over-year in Q2 FY26 from 28% the prior quarter, an 80% gross margin, and OpenAI spending that Stifel estimates ran $80-85m a quarter in FY25 and into the low $100m range in Q2 2026. Targets on file: Yorkville Ives $335, FBN $325, Stifel $305, Mizuho $300, Wedbush $275. Both GuruFocus and InvestingPro call the stock overvalued, the former at a GF Value of $205.66 against a trailing P/E near 600x versus a 419x five-year median.
SpaceX spectrum deal rippling through telecom
SPCX itself is only up 1.2%, but it's the driver behind a large share of the list. The headlines describe an $8bn acquisition of a nationwide low-band spectrum portfolio from Grain Management, at a reported $571m per MHz, aimed at Starlink Mobile. The carriers took the hit, with T-Mobile, AT&T and Verizon all sharply lower on the day, while tower REITs went the other way, Crown Castle reported up 19.87% in one headline. Barclays initiated SpaceX at Overweight and TD Cowen reiterated Buy with a $200 target. Other SpaceX items: Venezuela authorising Starlink to operate nationwide, and a public spat between Musk and Reliance's Ambani over Starlink's access to India, which India has rejected the monopoly framing of. Rocket Lab, flat on the day, also drew a Barclays Overweight initiation and a TD Cowen target cut to $90.
Joby, Teva and Oracle
Joby is down 5.4% at a 52-week low of $5.57, with Barclays downgrading to Underweight and cutting its target to $4. Teva is up 4.7% on FDA approval of Weltruza, a once-monthly injectable antipsychotic for schizophrenia. Oracle is up 4.6% with a crowded but headline-only item set: an insider buying roughly $3.5m of stock, GuruFocus showing GF Value of $194.91 against a $141.40 price, and several pieces framing the move around AI sentiment and scrutiny of OpenAI's numbers.
Smaller names and the rest
CRISPR Therapeutics is up 5.8% on reports ARK sold DraftKings and bought CRSP. Vertical Data is up 5.6% with two Form 4 filings and nothing else. Nio is up 5.0%, with only a "why is it surging" headline and no explanation given. Starfighters Space is down 4.8% on an 8-K covering a charter or bylaw amendment and a fiscal year change. Xometry +4.3%, Dave +4.3%, AngloGold +3.7%, AMC +3.5%, Itau +3.4% (Goldman raised its target to $10.50) and On Holding +3.1% are all headline-only valuation or ratings notes. Coherent is up 3.4% alongside Lumentum's CEO saying AI components are sold out through 2029. Arista +2.7% has CEO Jayshree Ullal selling over $21m of stock.
Quiet, but worth a glance
Netflix is down 1.8% on a Puck News report that it plans to cut 5% of its workforce. Apple is down 1.1% on reports of iPhone 18 Pro order cuts, with Evercore ISI reiterating its rating on lead-time data. TSMC is down 1.0% despite a 55% September sales rise and a Q3 revenue beat. Everything else on the list, including Micron, Broadcom, Costco, Astera Labs and Marathon Petroleum, moved less than a couple of percent on routine filings and analyst target tweaks.
Veea leads the board on an 8-K
The largest move in the list is Veea, up 47.3%, and the only item behind it is a headline-only SEC filing: an 8-K covering Item 5.02 (departure or election of directors and officers, and compensatory arrangements) plus an Item 8.01 "other events" disclosure. Nothing in the material explains the size of the move, so if this one matters to you, the filing itself is the place to go.
OPNW down on a Form 4
OPNW is off 17.0%. The only item attached is a VerifyMe Form 4 notice dated 9 October, and the article carries no detail beyond the filing's existence. No stated reason for the drop.
AST SpaceMobile breaks to a 52-week low
ASTS fell 10.5% and this is the most heavily covered name in the section, with seven items read in full. The driver is competitive and regulatory: the FCC authorised SpaceX to build a 15,000-satellite direct-to-cell network using its own spectrum, which cuts at AST's model of selling through wireless carriers. On top of that, investors got an early look at the FCC's 29 October agenda, which includes a proposal to open more airwaves to leasing under Supplemental Coverage from Space rules and a second proposal to auction 25 MHz in bands usable for direct-to-device. Clear Street called it a mixed signal and kept its Buy. The stock had already been weak going in: a B. Riley downgrade to Neutral on 2 October with the target cut from $85 to $65, a William Blair cut to its 2027 revenue estimate from $752m to $459m on launch delays, six consecutive earnings misses, a $125.9m write-off on the BlueBird 7 satellite failure, and a $1bn convertible offering that pushed the 45-satellite constellation target into early 2027. Shares touched $49.25 against a prior 52-week low of $49.31 and sit roughly 61% below the $133.86 high. Roth MKM kept Buy at $108 and Berenberg's Michael Filatov reaffirmed Buy, arguing the Grain Management spectrum sale to SpaceX actually raises AST's value as a carrier-aligned partner. AST's own pitch, per its CEO, is that domestic carrier partners hold about 1,000 MHz of low and mid-band spectrum its constellation can use, plus its own 45 MHz L-band allocation, targeting peak speeds near 200 Mbps. AT&T and Verizon arrangements are described as intact. Options were busy: 253,920 contracts with calls at 158,506 versus 95,414 puts, though the single biggest line was the Jan 2027 $50 put at 10,372 contracts, and three-month volatility rose 4.55 points to 81.31%. On fundamentals, GuruFocus flags a GF Score of 44/100, P/S of about 120 against a historical median near 62, and insider selling of $451.6m against $0.8m of buying over twelve months. Its own GF Value of $579.19 is labelled a possible value trap by the same publisher.
Sezzle jumps 9.7% with no news attached
Sezzle rose 9.7% to close at $128.64, inside a 52-week range of $49.50 to $195.71, on volume of 669,317 against a 620,915 average. None of the three items explains why. A Form 144 was filed for 10 October, GuruFocus puts GF Value at $95.31 (a 35% premium to the current price) with a GF Score of 81/100 and insider net selling of $26.7m over the past year, and TD Cowen maintained Buy on 6 October while trimming its target from $165 to $160. Earnings are dated 4 November.
Datadog hits an all-time high
Datadog gained 7.1% to $293.26, an all-time high, taking market cap to about $105bn and year-to-date return to roughly 101%. CIBC's Todd Coupland maintained Outperformer and raised his target from $280 to $315. That sits alongside a thick run of recent coverage: Yorkville Ives at $335, FBN Securities at $325, Wedbush at $275, Mizuho at $300 and Stifel at $305, with Wedbush citing revenue growth accelerating to 36% year-over-year in fiscal Q2 2026 and Stifel pointing to OpenAI's spend with Datadog, around $80-85m a quarter in FY25 and into the low $100m range in Q2 2026. Against that, insider selling is heavy: CTO Alexis Le-Quoc sold 53,912 Class A shares for $14.75m on 7 October under a 10b5-1 plan set up in June 2025, leaving him with 488,033 shares directly, and GuruFocus counts $913.5m of insider sales over twelve months with no purchases. GF Value is $205.66, making the stock 42.6% overvalued on that measure, with a GF Score of 84/100 and a trailing P/E of 598.5x against a five-year median of 418.9x.
Joby downgraded, hits 52-week low
Joby Aviation is down 5.4%, hitting a 52-week low of $5.57. The headlines state Barclays downgraded it to Underweight and cut its price target to $4. That's all these items say; no further detail was read.
Teva FDA approval, Oracle rebound
Teva is up 4.7% on headlines reporting FDA approval of Weltruza, a once-monthly injectable antipsychotic for schizophrenia. Oracle rose 4.6% with a cluster of headline-only items pointing in several directions: an insider purchase described as $3.5m, renewed scrutiny of OpenAI metrics alongside Microsoft, and several chart pieces around the $141-144 area. GuruFocus notes a GF Value of $194.91 against a price of $141.40. Nothing here was read in full.
The SpaceX spectrum deal running underneath everything
The single connecting thread across the section is SpaceX's roughly $8bn acquisition of a nationwide low-band spectrum portfolio from Grain Management, priced in one headline at $571m per MHz. That's the same event sitting behind the ASTS drop, and headline-only items show it knocked AT&T, Verizon and T-Mobile lower while lifting tower REITs, with options desks active in all three telecoms. Barclays initiated SpaceX at Overweight and TD Cowen reiterated Buy with a $200 target; Barclays also initiated Rocket Lab at Overweight, while TD Cowen cut its RKLB target to $90. Separately, Venezuela authorised Starlink to operate nationwide, and Musk publicly accused Ambani of blocking Starlink in India, which India rejected. SPCX itself was up only 1.2%.
Apple soft on iPhone 18 Pro order reports
Apple is down 1.1% against a heavy but headline-only news flow, the recurring item being reported order cuts to the iPhone 18 Pro on demand concerns, with suppliers named as affected. Evercore ISI reiterated its rating citing iPhone lead times. Other headlines flag a touchscreen MacBook and iPad mini refresh said to be coming 27 October, and an expanded $212m China clean energy fund.
The rest of the list
Everything else is small moves and routine filings. CRSP +5.8% on ARK buying while selling DraftKings, VDTA +5.6% on Form 4s, NIO +5.0% with a "why is it surging" headline that wasn't read, FJET -4.8% on an 8-K covering bylaw amendments. Mid-single-digit gainers with analyst or score headlines only: Xometry, Dave, AngloGold, AMC, Coherent and Itau, On Holding, Arista. Coherent's move is tied to Lumentum's CEO reportedly saying AI components are sold out through 2029. Netflix is down 1.8% on reports via Puck News that it plans to cut 5% of its workforce. Astera Labs slipped 1.4% after a Northland downgrade on valuation. Micron, Broadcom, Costco, Accenture and the remaining names moved less than 1% on filings and target tweaks.
Veea jumps on governance fix
VEEA is the biggest mover on the list, up 47.3%. Veea said on October 8 that it resolved all outstanding Nasdaq corporate governance deficiencies: Alan Black was added to the Compensation Committee, Kanishka Roy to the Audit Committee, and board member Helder Antunes resigned to restore an independent-director majority, though he stays on as executive VP and chief revenue officer. The GuruFocus piece pairs that with a hard look at the fundamentals behind a $12 million market cap: price-to-sales of 19.2 against a historical median near 109, trailing EPS of -2.80, a GF Score of 4 out of 100, financial strength rated 1 out of 10, an Altman Z-Score of -11.69, and no insider buying in the past twelve months. So the catalyst is a listing-compliance fix, not an operating change.
AST SpaceMobile at a 52-week low
ASTS is down 10.5% and traded to a fresh 52-week low, below the prior $49.31 mark, leaving it roughly 61% under its $133.86 high. The driver is SpaceX: the FCC authorized SpaceX to build a 15,000-satellite direct-to-cell network using its own spectrum, which bypasses the carrier relationships AST's model depends on. On top of that, the FCC's October 29 agenda came out a day early and includes a proposal to auction 25 MHz in bands usable for direct-to-device, which Clear Street called a mixed signal while keeping its Buy. The stock was already carrying a B. Riley downgrade to Neutral with a $65 target from October 2, a William Blair cut to its 2027 revenue estimate from $752 million to $459 million on launch delays, six straight earnings misses, a $125.9 million write-off on the BlueBird 7 failure, and a $1 billion convertible that pushed the 45-satellite target into early 2027. Roth MKM kept Buy at $108. One TradingView note cites Q2 2026 revenue of $31.5 million against a $230.9 million net loss, pro forma liquidity above $3.7 billion, and FY2026 guidance of $150-200 million.
The other side of the ASTS story
Two GuruFocus pieces on the same name read the SpaceX news the other way. Berenberg's Michael Filatov reaffirmed Buy, arguing the pending FCC approval of Grain Management's nationwide spectrum sale to SpaceX makes AST more relevant as the carrier-aligned satellite partner. Separately, AST's CEO pointed out that its domestic telecom partners hold roughly 1,000 MHz of low and mid-band spectrum that its constellation can use, plus its own 45 MHz L-band allocation, targeting peak speeds near 200 Mbps. Both notes flag the same uncomfortable numbers: price-to-sales around 120 versus a 62 median, GF Score 44 out of 100, profitability 1 out of 10, and insiders selling $451.6 million of stock over twelve months against $0.8 million bought. Options flow Friday was 253,920 contracts, 158,506 calls to 95,414 puts, with heavy fresh call buying at the Oct 16 $50 and $55 strikes and the single largest contract being the Jan 2027 $50 put at 10,372. Three-month implied vol rose 4.55 points to 81.3%.
SpaceX spectrum deal rippling across telecom
The same event sits behind a large cluster of headline-only items. SpaceX is up 1.2% after announcing an $8 billion acquisition of a nationwide low-band spectrum portfolio (reported elsewhere as 800 MHz from Grain Management), and the headlines describe telecom stocks falling on it in both the US and Europe, with Deutsche Telekom off 7%. The Investing.com market-mover tables in several of these articles show T-Mobile -13.3%, AT&T -9.9% and Verizon -8.8%, while tower names rallied, Crown Castle +15.6%, American Tower +9.3% and SBA +7.3%, with Goldman calling the deal a positive for US towers. Barclays initiated SpaceX at Overweight and TD Cowen reiterated Buy with a $200 target. There is also a separate Musk-versus-Ambani spat over Starlink's India launch, which India has publicly rejected as a monopoly claim.
Sezzle and Datadog lead the upside
SEZL is up 9.7%, closing near $129 on volume slightly below its 20-day average, with the Yahoo quote page showing a 52-week range of $49.50 to $195.71, trailing P/E of 28.1, revenue of $531.9 million and a TD Cowen note from October 6 that maintained Buy while trimming its target from $165 to $160. DDOG is up 7.1% at an all-time high of $292.80, a $105 billion market cap and a 101% year-to-date return. The supporting detail: 80% gross margin, revenue growth that accelerated to 36% year-over-year in fiscal Q2 2026 from 28% the prior quarter per Wedbush, and a Stifel estimate that OpenAI's spend with Datadog hit the low $100 million range in Q2. CIBC raised its target to $315 on Friday; Yorkville Ives, FBN and Wedbush have initiated at Outperform with $335, $325 and $275.
Joby at a 52-week low on a Barclays cut and a jury verdict
JOBY is down 5.5%, touching a 52-week low near $5.39 against an $18.77 high, down about 65% over the year. Barclays moved it from Equal Weight to Underweight and cut the target from $6 to $4, questioning whether any single player can own the eVTOL market, whether Joby's aircraft meets broad payload requirements, and whether its plan to vertically integrate manufacturing, operations and servicing is realistic at its current scale. Still unresolved is a $116.9 million jury verdict in Tampa federal court awarding Aerosonic damages for breach of an NDA and misappropriation of trade secrets on air data probes, including exemplary damages for willful conduct; Joby disputes it and plans post-trial motions and appeal. A director also filed a Form 144 this month. On the other side, Q2 revenue was $38.6 million versus $24.2 million in Q1, with Blade contributing $36.2 million, and Joby has agreed to buy defense firm Resonant Sciences for about $500 million. H.C. Wainwright keeps Buy at $18; Cantor is Neutral. Insiders sold $52.8 million over twelve months with no buying.
Two Form 4 filings with no content behind them
OPNW is down 17% and VDTA up 6.8%, and in both cases the only item is a bare Form 4 filing notice (VerifyMe and Vertical Data respectively) with no transaction detail in the article at all. Neither piece explains the move, so if either position matters to you, the filing itself is where to look.
Oracle, Teva and the optics names
Oracle is up 4.7% on a thick run of headline-only items: a rally story, an insider buying $3.5 million of stock, a dividend piece, a data center growth forecast, and separate headlines about OpenAI metrics coming under scrutiny for Oracle and Microsoft. Teva is up 4.6%, with headlines stating FDA approval of Weltruza, a once-monthly injectable antipsychotic for schizophrenia, alongside a conference call transcript. Coherent is up 3.4%, with headlines attributing the move in optical networking names to Lumentum CEO comments that AI components are sold out through 2029. These are headlines only, so take them as what was stated, not as reported detail.
Apple soft on iPhone 18 Pro order cuts
AAPL is down 1.1%, and the headline cluster is consistent: Nikkei Asia reported Apple cutting iPhone 18 Pro component orders on sluggish demand, with one headline also tying production cuts to surging memory chip prices. Separate headlines flag an October 27 event with a touchscreen MacBook and M6 chip models, and Evercore ISI reiterating its rating on iPhone lead times. All headline-only.
The quiet rest
Nothing else on the list carries much. NIO is up 5.3% on a headline that asks why it is surging without answering in the title. Astera Labs is down 1.4% on a Northland downgrade on valuation. Netflix is off 1.8% with headlines about a reported 5% workforce cut (Puck News) and a Morgan Stanley target revision. TSMC is down 1.0% despite headlines citing a 55% September sales surge and a Q3 revenue beat. Rocket Lab is flat with a Barclays initiation at Overweight and a TD Cowen target cut to $90. The remainder is ETF flow notes, routine analyst reiterations and chart posts.
TradingView
Trading 212
